These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 33624341

  • 1. Gastrointestinal: Severe gastritis with complete gastric mucosal sloughing.
    Nasser R, Fisher Y, Klein A.
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2639. PubMed ID: 33624341
    [No Abstract] [Full Text] [Related]

  • 2. Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.
    Gambichler T, Doerler M, Scheel CH.
    Lupus; 2021 Mar; 30(3):531-533. PubMed ID: 33407044
    [No Abstract] [Full Text] [Related]

  • 3. Pembrolizumab in the Treatment of Breast Cancer.
    Pivot X.
    N Engl J Med; 2022 Jul 21; 387(3):273-274. PubMed ID: 35857664
    [No Abstract] [Full Text] [Related]

  • 4. Clinical Characteristics and Outcomes of Pembrolizumab Induced Gastritis: A Systematic Review of the Literature.
    Lei H, Sun W, Liu X, Wang C.
    J Gastrointest Cancer; 2024 Sep 21; 55(3):1-8. PubMed ID: 38787493
    [Abstract] [Full Text] [Related]

  • 5. Multiplexed imaging reveals an IFN-γ-driven inflammatory state in nivolumab-associated gastritis.
    Ferrian S, Liu CC, McCaffrey EF, Kumar R, Nowicki TS, Dawson DW, Baranski A, Glaspy JA, Ribas A, Bendall SC, Angelo M.
    Cell Rep Med; 2021 Oct 19; 2(10):100419. PubMed ID: 34755133
    [Abstract] [Full Text] [Related]

  • 6. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
    Yoshida S, Shiraishi K, Mito T, Sayama K.
    Clin Exp Dermatol; 2020 Oct 19; 45(7):908-911. PubMed ID: 32394515
    [No Abstract] [Full Text] [Related]

  • 7. CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.
    Menzies AM, Pires da Silva I, Trojaniello C, Vieu E, Amaria RN, Zimmer L, Lo SN, Burton EM, Tawbi HA, Schadendorf D, Grob JJ, Ascierto PA, Long GV.
    N Engl J Med; 2022 Apr 28; 386(17):1668-1669. PubMed ID: 35476655
    [No Abstract] [Full Text] [Related]

  • 8. Predicted Value of PD-L1 for Patients With Cervical Cancer Treated With Pembrolizumab.
    Luo PH, Mo DC, Wang HL, Liang XJ, Huang JF.
    J Clin Oncol; 2024 May 01; 42(13):1596. PubMed ID: 38452320
    [No Abstract] [Full Text] [Related]

  • 9. Gastric microbiota transplantation as a potential treatment for immune checkpoint inhibitor-associated gastritis.
    Ma BT, Sang LX, Chang B.
    World J Gastroenterol; 2024 Jun 28; 30(24):3123-3125. PubMed ID: 38983955
    [Abstract] [Full Text] [Related]

  • 10. Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis.
    Bello E, Cohen JV, Mino-Kenudson M, Dougan M.
    J Immunother Cancer; 2019 Feb 11; 7(1):41. PubMed ID: 30744698
    [Abstract] [Full Text] [Related]

  • 11. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab.
    Rao BB, Robertson S, Philpott J.
    Am J Gastroenterol; 2019 Feb 11; 114(2):196. PubMed ID: 30353060
    [No Abstract] [Full Text] [Related]

  • 12. Visceral Aneurysm Formation and Intraabdominal Hemorrhage Associated with Immune Checkpoint Inhibitor Therapy.
    Lee AY, Lam A, Hicks RM, Isikbay M, Heller MB, Sugi MD, Behr S, Kohi MP.
    J Vasc Interv Radiol; 2021 Jan 11; 32(1):151-152. PubMed ID: 33277167
    [No Abstract] [Full Text] [Related]

  • 13. Olaparib (Lynparza) for advanced ovarian cancer.
    Med Lett Drugs Ther; 2016 Feb 29; 58(1489):e32-3. PubMed ID: 26938702
    [No Abstract] [Full Text] [Related]

  • 14. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience.
    Fortes BH, Liou H, Dalvin LA.
    Br J Ophthalmol; 2021 Sep 29; 105(9):1263-1271. PubMed ID: 32830124
    [Abstract] [Full Text] [Related]

  • 15. IgA nephropathy after pembrolizumab therapy for mesothelioma.
    Wang R, Das T, Takou A.
    BMJ Case Rep; 2020 Nov 30; 13(11):. PubMed ID: 33257374
    [Abstract] [Full Text] [Related]

  • 16. PARP inhibitors for ovarian cancer.
    Med Lett Drugs Ther; 2017 Dec 04; 59(1535):200-202. PubMed ID: 29186085
    [No Abstract] [Full Text] [Related]

  • 17. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.
    Andersson NW, Zachariae C, Simonsen AB.
    Eur J Cancer; 2021 Mar 04; 145():168-170. PubMed ID: 33486439
    [No Abstract] [Full Text] [Related]

  • 18. Cediranib aims for a comeback.
    Schmidt C.
    J Natl Cancer Inst; 2015 Mar 04; 107(3):. PubMed ID: 25745013
    [No Abstract] [Full Text] [Related]

  • 19. Acute Ulceronecrotic Gastritis With Cytomegalovirus Reactivation: Uncommon Toxicity of Immune Checkpoint Inhibitors in Microsatellite Instability-High Metastatic Colorectal Cancer.
    Hulo P, Touchefeu Y, Cauchin E, Archambeaud I, Chapelle N, Bossard C, Bennouna J.
    Clin Colorectal Cancer; 2020 Dec 04; 19(4):e183-e188. PubMed ID: 32703755
    [No Abstract] [Full Text] [Related]

  • 20. Olaparib for the treatment of ovarian cancer.
    Bornstein E, Jimeno A.
    Drugs Today (Barc); 2016 Jan 04; 52(1):17-28. PubMed ID: 26937492
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.